Telix Pharmaceuticals Ltd ADR (TLX): Next-Year EPS Estimate 215.96%
As of 2026-06-18, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 215.96%. Featured in our EPS revision report on 2026-04-13.
On 2026-06-17, analyst consensus for TLX's next-year EPS growth shifted from 160.60% to 215.96% — a positive change of 55.36 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 258.83%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 215.96%
- EPS growth this year
- 258.83%
- EPS next quarter (est)
- N/A
- Last price
- $10.09
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-18 | 215.96% | 258.83% | N/A | $10.09 |
| 2026-06-17 | 215.96% | 258.83% | N/A | $9.94 |
| 2026-06-16 | 160.60% | 292.57% | N/A | $9.58 |
| 2026-06-15 | 160.60% | 292.57% | N/A | $9.54 |
| 2026-06-14 | 160.60% | 292.57% | N/A | $9.56 |
| 2026-06-11 | 160.60% | 292.57% | N/A | $9.45 |
| 2026-06-10 | 160.60% | 292.57% | N/A | $9.44 |
| 2026-06-09 | 160.60% | 292.57% | N/A | $9.41 |
| 2026-06-08 | 160.60% | 292.57% | N/A | $9.22 |
| 2026-06-07 | 160.60% | 292.57% | N/A | $9.30 |
| 2026-06-04 | 160.60% | 292.57% | N/A | $9.54 |
| 2026-06-03 | 160.60% | 292.57% | N/A | $8.77 |
| 2026-06-02 | 160.60% | 292.57% | N/A | $9.16 |
| 2026-06-01 | 162.79% | 291.37% | N/A | $9.42 |
| 2026-05-31 | 175.50% | 305.04% | N/A | $9.43 |
| 2026-05-28 | 173.27% | 306.33% | N/A | $9.53 |
| 2026-05-27 | 173.27% | 306.33% | N/A | $9.74 |
| 2026-05-26 | 173.27% | 306.33% | N/A | $9.57 |
| 2026-05-25 | 173.27% | 306.33% | N/A | $9.47 |
| 2026-05-24 | 173.27% | 306.33% | N/A | $9.47 |
| 2026-05-21 | 173.27% | 306.33% | N/A | $10.27 |
| 2026-05-20 | 173.27% | 306.33% | N/A | $10.28 |
| 2026-05-19 | 173.27% | 306.33% | N/A | $10.17 |
| 2026-05-18 | 175.50% | 305.04% | N/A | $10.28 |
| 2026-05-17 | 175.50% | 305.04% | N/A | $10.56 |
| 2026-05-14 | 175.50% | 305.04% | N/A | $10.86 |
| 2026-05-13 | 175.50% | 305.04% | N/A | $10.52 |
| 2026-05-12 | 175.50% | 305.04% | N/A | $10.39 |
| 2026-05-11 | 175.50% | 305.04% | N/A | $10.83 |
| 2026-05-10 | 175.50% | 305.04% | N/A | $10.68 |
Reports Featuring TLX
Recent News
- Telix and Regeneron Announce Strategic Radiopharma CollaborationGlobeNewswire
- FDA Accepts NDA for TLX101-Px (Pixclara)GlobeNewswire
Screen Performance
Aggregate stats across all 1795 tickers our top-EPS-revision screen has flagged over the past 78 days.
- Median return since detection
- +3.6%
- % of tickers in the green
- 58%
- Median return on winners
- +19.9%
- Large revisions captured
- 842
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Telix Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-06-18, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 215.96%, based on analyst consensus.
When was the latest EPS estimate revision for TLX?▾
The most recent revision occurred on 2026-06-17, when analysts adjusted the next-year EPS growth estimate from 160.60% to 215.96%.
What sector and industry does Telix Pharmaceuticals Ltd ADR belong to?▾
Telix Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TLX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Telix Pharmaceuticals Ltd ADR (TLX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports